How Much Did Replimune Raise?
Funding & Key Investors

Forbion

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating the company's philosophy that investments in companies should positively impact the health and well-being of patients.

Atlas Ventures

Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines. The firm partners with exceptional life science entrepreneurs to support the launch and growth of innovative biotech startups. With a deep commitment to advancing medical innovation, Atlas Venture helps transform promising scientific discoveries into real-world health solutions. Its team brings seasoned expertise and strategic insight to nurture emerging ventures across the biotech landscape.

Omega Funds

Richard joined Omega Funds in 2008. His career spans 25 years in private equity investing and strategic consulting, all within life science and healthcare. At Omega, he is a member of the firms investment committee and acts as President of Omega Fund Management LLC; his primary investment focus is in drug discovery and development companies, and is actively involved in the firms secondary buyout practice and investments in academic spinouts. Previously, Richard was a General Partner at MVM Life Science Partners, a life science-focused venture capital firm, where he founded the firms US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), where he specialized in healthcare growth capital and leveraged buyout transactions. Prior to SKM, now known as Apax Partners Inc., Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than three dozen small and large biotechnology firms. He was also an Associate with the M&A investment bank BT Wolfensohn. He has served on a number of boards of biotechnology, specialty pharmaceutical, and medical device companies. He serves on the advisory boards of the Deshpande Center at the Massachusetts Institute of Technology. Richard earned his AB and MBA degrees from Harvard University. Claudio joined Omega Funds in 2016. In addition to managing NeoMeds funds, Claudio assists with and advises on new investments for Omega and sits on the investment committee. Claudio joined NeoMed in 2001 and became a Partner in 2004. He has over 15 years experience of venture capital investing in healthcare in Europe and the US. Prior to NeoMed, Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut. Claudio has an MBA from Erasmus University, the Netherlands and a PhD degree in Genetics from the University of Pavia, Italy. Anne-Mari joined Omega Funds in 2009 ...